Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559332 | 0.86 | KDM4E (0.40) | PDE10AADORA2AADORA1ALDH1A1NPSR1 | |
| SCHEMBL29308077 | 0.86 | PDE10A (0.52) | PDE10AADORA2AADORA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24309857 | 0.82 | PDE10A (0.35) | PDE10AADORA2AADORA1ALDH1A1DPP4 | |
| SCHEMBL15504765 | 0.78 | ADORA2A (0.37) | PDE10AADORA2AADORA1ALDH1A1HSP90AB1 | |
| SCHEMBL11585561 | 0.78 | NUDT1 (0.43) | PDE10AADORA2AADORA1ALDH1A1NPSR1 | |
| SCHEMBL23852245 | 0.78 | TLR8 (0.36) | PDE10AADORA2AADORA1ALDH1A1KDM4E | |
| SCHEMBL11059135 | 0.78 | CCNA2 (0.46) | PDE10AADORA2AADORA1NPSR1HSP90AB1 | |
| SCHEMBL19242058 | 0.78 | HEXA (0.47) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL23998054 | 0.77 | HSP90AA1 (0.38) | PDE10AADORA2AADORA1ALDH1A1HSP90AB1 | |
| SCHEMBL30322567 | 0.77 | HSP90AA1 (0.38) | PDE10AADORA2AADORA1ALDH1A1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2680847-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. (CZ) | 2014-01-08 | — | — | EP | claimed |
| US-20130324566-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CR, v.v.i. (CZ) | 2013-12-05 | — | — | US | claimed |
| WO-2012116666-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, v.v.i. (CZ) | 2012-09-07 | — | — | WO | claimed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883576-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4558498-A1 | NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546608-A | Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-115611867-B | (1, 1-Trichloro-2) carbamate derivative and preparation method and application thereof | 中南大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20130324566-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CR, v.v.i. (CZ) | 2013-12-05 | — | — | US | disclosed |
| US-8268846-B2 | Amino heterocyclic linked pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012116666-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, v.v.i. (CZ) | 2012-09-07 | — | — | WO | disclosed |
| US-20100016344-A1 | AMINO HETEROCYCLIC LINKED PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7557209-B2 | Process for the preparation of (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol | GLAXO GROUP LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070027316-A1 | Process for the preparation of (1s, 4r)-cis-4-'2-amino-6chloro-9h-purin-yl!-2-cyclopentene-1- methanol | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016344-A1 | AMINO HETEROCYCLIC LINKED PYRIMIDINE DERIVATIVES | DPYD, TYMS, UMPS | PDE10A 2220/4885ADORA2A 738/4885ADORA1 1373/4885 |
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | PDE10A 2665/4885ADORA2A 532/4885ADORA1 985/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | PDE10A 2261/4885ADORA2A 448/4885ADORA1 777/4885 |
| US-20130324566-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | PTGIS, PTGS2, PTGES2 | PDE10A 576/4885ADORA2A 110/4885ADORA1 215/4885 |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2B, ADORA2A, ADORA3 | PDE10A 587/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20070027316-A1 | Process for the preparation of (1s, 4r)-cis-4-'2-amino-6chloro-9h-purin-yl!-2-cyclopentene-1- methanol | TPMT, UGT1A1, TYMP | PDE10A 2359/4885ADORA2A 167/4885ADORA1 172/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | PDE10A 1408/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.